H. Killick

Oxidised IL-33 signals via RAGE/EGFR to drive a COPD-associated phenotype

G. Sims, E. S. Cohen, D. G. Rees, 2022, 03.02 - Airway cell biology and immunopathology.

Safety, Pharmacokinetics and Immunogenicity of the Anti-Interleukin-33 Antibody, Tozorakimab: Results of a Phase 1 Study in Healthy Adults and Patients with Chronic Obstructive Pulmonary Disease

D. Singh, R. Moate, E. Jiménez, 2022, B21. BASIC, CLINICAL, AND TRANSLATIONAL COPD STUDIES: THE ONGOING HUNT FOR UNDERLYING MECHANISMS AND THERAPEUTIC TARGETS.

Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex

J. Erjefält, G. Sims, E. S. Cohen, 2023, European Respiratory Journal.